Informatics for Consumer Health

Catalent Announces New Operating Structure

Retrieved on: 
Tuesday, July 5, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Acquisition, Patient, Securities Act of 1933, CTLT, Achievement, Information, Securities Exchange Act of 1934, S&P, Senior, Engineering, COVID-19, Growth, Pharma, Failure, Oral, Industry, Goal, Phrase, Informatics for Consumer Health, Gennadius, Technology, Energy Independence and Security Act of 2007, NYSE, Softgel, General counsel, Health, Maselli, Solution, Leadership, Information technology, Excipient, Group, Transformation, Fine chemical, Management, Risk management, Catalent

This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.

Key Points: 
  • This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.
  • Our industry continues to demonstrate steady growth, and this new structure will allow us to be more agile in meeting and anticipating customer needs and expectations, said Maselli.
  • Among other benefits, it will create commercial synergies for our customers, as they will be better able to access the full range of Catalent services applicable to their molecules.
  • Karen has played a critical role on the Executive Leadership Team since joining Catalent in early 2020.

Juggy Sihota appointed as Board Chair of VGH & UBC Hospital Foundation

Retrieved on: 
Thursday, June 30, 2022
Acquisition, Board of directors, CEO, Adult, Research, GLOBE, Marketing, Foundation, Growth, BIPOC, Vancouver Coastal Health, Informatics for Consumer Health, Elena Kagan Supreme Court nomination, UBC Hospital, TELUS, Partnership, Sihota, Chairperson, VGH, Vancouver Hospital and Health Sciences Centre, HR, Time, Board, Health, Hospital, Management

VANCOUVER, British Columbia, June 30, 2022 (GLOBE NEWSWIRE) -- Today, VGH & UBC Hospital Foundation is announcing Juggy Sihota, Vice-president, Consumer Health at TELUS, as its newly appointed Board Chair.

Key Points: 
  • VANCOUVER, British Columbia, June 30, 2022 (GLOBE NEWSWIRE) -- Today, VGH & UBC Hospital Foundation is announcing Juggy Sihota, Vice-president, Consumer Health at TELUS, as its newly appointed Board Chair.
  • I have had the privilege of serving on the VGH & UBC Hospital Foundation Board for the past nine years since they helped save my moms life.
  • We are very excited to announce the appointment of Juggy Sihota as our next Chair of the Board of Directors, Angela Chapman, President & CEO of VGH & UBC Hospital Foundation.
  • VGH & UBC Hospital Foundation is Vancouver Coastal Health s primary philanthropic partner, raising funds for specialized adult health services and research for all British Columbians.

Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments

Retrieved on: 
Wednesday, June 8, 2022
Zero, Wolk, Basel Institute on Governance, Goal, Company, Race, ESG, Behavior, Business, Enterprise, Nursing, Multimedia, Tuberculosis, Sustainable Development Goals, NYSE, COVID-19, To Err Is Human (report), Culture, History, Communication, U.S. Securities and Exchange Commission, Sustainability accounting, Jose Duato, Government, Work, Johnson & Johnson, HIV, Heart, Foundation, Carbon, Corporation, Patent, Annual report, Webcast, Security (finance), United Nations Sustainable Development Group, Family, Global, Humanity, Outline, Risk, Sustainability Accounting Standards Board, Community, Patient, Compliance, GRI, JNJ, Private Securities Litigation Reform Act, Woman, Science, Norges Bank, Research, Director, CDP, United Nations, Environment, Informatics for Consumer Health, Etto, Growth, Environmental health, Pharmaceutical industry, Health

NEW BRUNSWICK, N.J., June 8, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today published its 2021 Health for Humanity Report , which shares progress against its purpose-driven Health for Humanity 2025 Goals and serves as its annual disclosure on environmental, social and governance (ESG) performance.

Key Points: 
  • NEW BRUNSWICK, N.J., June 8, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today published its 2021 Health for Humanity Report , which shares progress against its purpose-driven Health for Humanity 2025 Goals and serves as its annual disclosure on environmental, social and governance (ESG) performance.
  • In 2021, we continued to focus on solving challenging global health issues that align with our ESG strategic priorities.
  • The Foundation operates worldwide as Johnson & Johnson Foundation US (founded 1953) and Johnson & Johnson Foundation Scotland (founded 2007).
  • At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.

Willem Appelo to succeed Sophie Bechu as Philips’ Chief Operations Officer

Retrieved on: 
Tuesday, June 7, 2022
Dignity, Barrow Neurological Institute, Time, Health, Medical device, Medical Technology Group, Johnson & Johnson, Knowledge, Xerox, CEO, AWS, Innovation, Informatics for Consumer Health, List of life sciences, Pharma, Digital, Dignity Health, Construction Research and Innovation Strategy Panel, AEX, NYSE, Bram Appelo, PHG, Supply, Amazon Web Services, Amazon, Technology, Pharmaceutical industry, Health care, MD

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Willem (Wim) Appelo will join Philips Executive Committee, effective July 18, 2022, and succeed Sophie Bechu as Chief Operations Officer per October 1, 2022.

Key Points: 
  • Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Willem (Wim) Appelo will join Philips Executive Committee, effective July 18, 2022, and succeed Sophie Bechu as Chief Operations Officer per October 1, 2022.
  • Mr. Appelo will report to Philips CEO Frans van Houten and work closely with Mrs. Bechu to ensure a seamless transition.
  • I am very pleased that Wim Appelo will be joining Philips as our new Chief Operations Officer, said Frans van Houten, CEO of Royal Philips.
  • Mr. Appelos appointment to Philips Executive Committee builds on last years appointment of Shez Partovi, MD, as Chief Medical, Innovation & Strategy Officer, and member of Philips Executive Committee.

Bayer Appoints Two New Members to U.S. Country Leadership Team

Retrieved on: 
Wednesday, June 1, 2022
FDA, Other Health, Practice Management, Pharmaceutical, Managed Care, General Health, Medical Devices, Infectious Diseases, Fitness & Nutrition, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Medical Supplies, Leadership, Health For All, Head, Climate, Goal, HR, CFO, Trust, The Climate Corporation, Group, Retirement, Senior, Workforce, Informatics for Consumer Health, Multimedia, Human resources, Growth, Ageing, Pharmaceutical industry, Management, Hunger, Bayer, Health

Bayer, one of the countrys leading life-sciences companies, today announced two changes to its U.S. Country Leadership Team.

Key Points: 
  • Bayer, one of the countrys leading life-sciences companies, today announced two changes to its U.S. Country Leadership Team.
  • Branca has been with Bayer since 2006 and most recently served as Bayer U.S. Vice President and Treasurer.
  • He has held numerous financial leadership roles throughout his tenure with the company, including serving as CFO for the Climate Corporation and holding multiple finance functional leadership roles.
  • Marina joined the company in 2021 as Vice President, Human Resources for Bayer Pharmaceuticals Americas, leading Human Resources for the Americas Pharmaceuticals organization.

Democratising Personalisation in Consumer Health and Beauty Markets, 2022 Market Report - ResearchAndMarkets.com

Retrieved on: 
Monday, May 23, 2022
Cosmetics, Retail, Goal, Industry, Acquisition, COVID-19, Technology, Informatics for Consumer Health, Beauty salon, Health, Beauty

The "Democratising Personalisation in Health and Beauty" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Democratising Personalisation in Health and Beauty" report has been added to ResearchAndMarkets.com's offering.
  • The Democratising Personalisation in Health and Beauty global briefing examines the size, growth trends and potential opportunities in the Consumer Health market.
  • Interest in personalised approaches to health and beauty has surged since COVID-19, as improvements in technology have been met by a more accepting public focused on health outcomes and demanding products that fit their unique goals.
  • The strategic analyses include assessing the impacts of changing regulations, research breakthroughs and public health concerns on both the market and leading companies.

Rising Star Corporate/M&A Lawyer Jenny Hochenberg Joins Freshfields’ Market-Leading Team

Retrieved on: 
Thursday, May 19, 2022
Legal, Professional Services, GW Pharmaceuticals, Atlas, Health, Atmosphere of Earth, Lawyer, Platinum Equity, Woman, Jazz Pharmaceuticals, Scientific Games, Johnson & Johnson, Canadian National Railway, AT, Savoy Hotel, Atlas Air, Commonwealth of Australia (US Corporation), WarnerMedia, Sterilization, Atmosphere, Fidelity, OpenBet, List, Platinum, Technology, Sale, Clearwave Communications, Corporation, Fortive, LifeScan, Acquisition, American Justice, Informatics for Consumer Health, Property management, Pharmaceutical industry, Momenta, Freshfields Bruckhaus Deringer, Amazon

Ms. Hochenbergs practice focuses on representing corporations in mergers and acquisitions, shareholder activism and takeover defense and corporate governance.

Key Points: 
  • Ms. Hochenbergs practice focuses on representing corporations in mergers and acquisitions, shareholder activism and takeover defense and corporate governance.
  • Jenny is one of the smartest and most capable corporate lawyers Ive ever seen, and Im thrilled that shes chosen to join Freshfields.
  • She is creative, dedicated and relentless in service of her clients, and is one of the true rising stars in the M&A community in the United States.
  • She is also an amazing person to work with, and she will fit in wonderfully with the rest of our exceptional team.

REACTINE® and Tree Canada collaborate to improve the lives of Canadians

Retrieved on: 
Thursday, May 19, 2022
Tree Canada, 2010 Johnson & Johnson children's product recall, Sneeze, Private Securities Litigation Reform Act, McNeil Consumer Healthcare, Climate change, Camping, U.S. Securities and Exchange Commission, RL, Listerine, Seedling, Greenhouse effect, Science, Health, Itchy, Tree, Nature, National academy, EST, Tylenol, Aveeno, OGX, Johnson & Johnson, Method, Research, Carbon, Pollen, Partnership, Nasal congestion, Instagram, Air pollution, Nose, Behavior, Neutrogena, Oxygen, Security (finance), Risk, Annual report, Informatics for Consumer Health, Pharmaceutical industry

As part of this collaboration, REACTINE is sponsoring a portion of Tree Canada's National Greening Program, where more than 800,000 trees will be planted across Canada this year.

Key Points: 
  • As part of this collaboration, REACTINE is sponsoring a portion of Tree Canada's National Greening Program, where more than 800,000 trees will be planted across Canada this year.
  • REACTINE will be working with Tree Canada to support the planting of more than 5,800 seedlings across the country as part of Tree Canada's National Greening Program.
  • "We are thrilled to be partnering with REACTINE," says Michael Petryk, director of operations, Tree Canada.
  • REACTINE is owned byToronto, ON-based, McNeil Consumer Healthcare, division of Johnson & Johnson Inc.
    For more information on REACTINE products, please visit Reactine.ca or www.Facebook.com/ReactineCA .

Brightseed Closes $68M To Accelerate A.I.-Led Exploration of Nature for Health Solutions

Retrieved on: 
Tuesday, May 10, 2022
COO, CTO, Medicine, Metabolomics, Food, Center for Nutrition Policy and Promotion, Pharmavite, Curcumin, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Science, Immunity, Science center, A.I, Organization, FDA, Human, Environment, Industry, Non-governmental organization, Maternal health, Temasek, Informatics for Consumer Health, Health, Ocean Spray, Plant, Aspirin, Nature, Botany, Solution, CEO, SAN, Caffeine, Drink, Pharmaceutical industry, Forager

SAN FRANCISCO, May 10, 2022 /PRNewswire-PRWeb/ -- Brightseed, a biosciences company and creator of Forager®, a computational platform that illuminates the connections between nature and human health, today announced $68 million in Series B funding led by Temasek, with participation from existing and new investors. The new funding will enable Brightseed to advance natural compound discovery and clinical validation, and launch the company's first FDA-GRAS ingredient from a new commercialization center in Raleigh, North Carolina.

Key Points: 
  • "Discovering and mapping natural bioactives to human health benefits was just the first step for Brightseed.
  • Now, we're launching clinically-studied ingredients and insights to illuminate the hidden potential in nature to restore human health."
  • "Brightseed is building the opportunity space for health innovation rooted in nature, and delivering a clear path forward for clinical validation.
  • that discovers and maps the bioactive compounds in nature and understands which of them have the greatest impact on human health.

Rimidi and ARKRAY Partner to Bring Glucose Data from the GLUCOCARD® Shine Connex Blood Glucose Monitoring System to the EHR

Retrieved on: 
Monday, May 9, 2022
Diabetes, Population, Twitter, Gaps, Blood, Death, Time, Patient, Doctor of Philosophy, Partnership, Bluetooth, MD, Workflow, Informatics for Consumer Health, Health, LinkedIn, Solution, CEO, Medical imaging, Medical device, Medicine, Facebook

ATLANTA, May 9, 2022 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences, and achieve quality objectives, today announced a new partnership with ARKRAY, a leader in diabetes care products. As a result of the collaboration, ARKRAY's GLUCOCARD® Shine Connex Blood Glucose Monitoring System is now integrated with the Rimidi Platform, making blood glucose data more actionable for providers and patients alike.

Key Points: 
  • As a result of the collaboration, ARKRAY's GLUCOCARD Shine Connex Blood Glucose Monitoring System is now integrated with the Rimidi Platform , making blood glucose data more actionable for providers and patients alike.
  • As a result, it is critical patients have access to reliable and affordable blood glucose monitoring systems that meet industry accuracy standards and enable more patients to test as often as needed.
  • The integration between Rimidi and ARKRAY enables providers to see blood glucose data in their existing workflows, thus providing a more comprehensive view of patients' health, and in turn driving better clinical decisions.
  • For more information on Rimidi's partnership with ARKRAY, as well as Rimidi's additional solutions and offerings for chronic condition patients, visit http://www.rimidi.com .